ResearcherUniversity of MacauActive in the last 2 years

Ruiyu Xie

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0003-0518-2897; OpenAlex author ID A5005070709.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Collaborators: 3

Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.202501774 ↗
Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo. Co-author DOI 10.1016/j.ejps.2017.05.057 ↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Shuai Liu · 1 shared paper, 2025
- Paper The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.202501774 ↗
Jie Ye · 1 shared paper, 2017
- Paper Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo. DOI 10.1016/j.ejps.2017.05.057 ↗
Hang Fai Kwok · 1 shared paper, 2017
- Paper Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo. DOI 10.1016/j.ejps.2017.05.057 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.